Evidence map›Paper›PMID 28727820›Full record

ArticlePloS one2017

Active hexose-correlated compound enhances extrinsic-pathway-mediated apoptosis of Acute Myeloid Leukemic cells.

Kavin Fatehchand, Ramasamy Santhanam, Brenda Shen, Ericka L Erickson, Shalini Gautam, Saranya Elavazhagan, Xiaokui Mo, Tesfaye Belay, Susheela Tridandapani, Jonathan P Butchar

Open access · goldAbstract read
In one paragraph

Article in PloS one, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 8 papers.

0numbers the graph read from it
0cells of the map it votes in
8citing papers in PubMed
1.1field-weighted citation impact, top 22% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

8 citing papers in PubMed, 12 citations in OpenAlex.

  1. Anticancer activities of natural abietic acid.Frontiers in pharmacology · 2024
    Review
  2. Article
  3. A standardized extract of culturedOncology letters · 2021
    Article
  4. Article
  5. Review
  6. Review
  7. Future in the Past:International journal of molecular sciences · 2018
    Article
  8. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors at 2 institutions in 1 country.

Kavin FatehchandMedical Scientist Training Program, The Ohio State University, Columbus, Ohio, United States of America.
Ramasamy SanthanamDepartment of Internal Medicine, The Ohio State University, Columbus, Ohio, United States of America.
Brenda ShenDepartment of Internal Medicine, The Ohio State University, Columbus, Ohio, United States of America.
Ericka L EricksonDepartment of Internal Medicine, The Ohio State University, Columbus, Ohio, United States of America.
Shalini GautamDepartment of Internal Medicine, The Ohio State University, Columbus, Ohio, United States of America.
Saranya ElavazhaganDepartment of Internal Medicine, The Ohio State University, Columbus, Ohio, United States of America.
Xiaokui MoCenter for Biostatistics, The Ohio State University, Columbus, Ohio, United States of America.
Tesfaye BelaySchool of Arts and Sciences, Bluefield State University, Bluefield, WV, United States of America.
Susheela TridandapaniMedical Scientist Training Program, The Ohio State University, Columbus, Ohio, United States of America.
Jonathan P ButcharDepartment of Internal Medicine, The Ohio State University, Columbus, Ohio, United States of America.ORCID http://orcid.org/0000-0002-7328-7853
The Ohio State University · USBluefield State College · US

Funding

Translational Therapeutics Research Program (TT)P30CA016058 · NCI · OHIO STATE UNIVERSITY · PI Jennifer A. Woyach · 1985 to 2026
$132.3M
WV INBRE: The Inhibitor of Growth Family Member 4 (ING4) inhibits L-Type Amino Acid Transporter 1 (LAT1) expression to suppress Breast CancerP20GM103434 · NIGMS · MARSHALL UNIVERSITY · PI Travis Salisbury · 2012 to 2026
$61.1M
TWO SIGNAL REQUIREMENT FOR NATURAL KILLER IMMUNITYP01CA095426 · NCI · OHIO STATE UNIVERSITY · PI CALIGIURI, MICHAEL A · 2002 to 2016
$29.6M
Myeloid cell-derived Granzyme B as an inducible enhancer of cancer immunotherapyR01CA203584 · NCI · OHIO STATE UNIVERSITY · PI BUTCHAR, JONATHAN P., TRIDANDAPANI, SUSHEELA · 2017 to 2021
$1.7M
Novel monocyte effector function in CLL immune therapyR01CA162411 · NCI · OHIO STATE UNIVERSITY · PI BYRD, JOHN C., TRIDANDAPANI, SUSHEELA · 2013 to 2017
$1.6M
Effects and mechanisms of cold-induced stress on the development of chlamydia genital infection in a mouse modelR15AI124156 · NIAID · BLUEFIELD STATE UNIVERSITY · PI BELAY, TESFAYE · 2016 to 2016
$423k
Analysis of the novel phenomenon of antibody-mediated fratricide in Acute Myeloid LeukemiaF30CA217006 · NCI · OHIO STATE UNIVERSITY · PI FATEHCHAND, KAVIN · 2017 to 2019
$139k
NCI NIH HHS F30 CA217006NCI NIH HHS P01 CA095426NCI NIH HHS P30 CA016058NCI NIH HHS R01 CA162411NCI NIH HHS R01 CA203584NIAID NIH HHS R15 AI124156NIGMS NIH HHS P20 GM103434
6 · The paper itself

Abstract

Active Hexose Correlated Compound (AHCC) has been shown to have many immunostimulatory and anti-cancer activities in mice and in humans. As a natural product, AHCC has potential to create safer adjuvant therapies in cancer patients. Acute Myeloid Leukemia (AML) is the least curable and second-most common leukemia in adults. AML is especially terminal to those over 60 years old, where median survival is only 5 to 10 months, due to inability to receive intensive chemotherapy. Hence, the purpose of this study was to investigate the effects of AHCC on AML cells both in vitro and in vivo. Results showed that AHCC induced Caspase-3-dependent apoptosis in AML cell lines as well as in primary AML leukopheresis samples. Additionally, AHCC induced Caspase-8 cleavage as well as Fas and TRAIL upregulation, suggesting involvement of the extrinsic apoptotic pathway. In contrast, monocytes from healthy donors showed suppressed Caspase-3 cleavage and lower cell death. When tested in a murine engraftment model of AML, AHCC led to significantly increased survival time and decreased blast counts. These results uncover a mechanism by which AHCC leads to AML-cell specific death, and also lend support for the further investigation of AHCC as a potential adjuvant for the treatment of AML.

Indexed as

AnimalsAntineoplastic AgentsApoptosisBlotting, WesternCaspase 3Caspase 8Cell Line, TumorCell SurvivalDose-Response Relationship, DrugDrug Evaluation, Preclinicalfas ReceptorFemaleLeukemia, Myeloid, AcuteMice, SCIDMonocytesNeoplasm TransplantationActive Hexose Correlated CompoundAntineoplastic AgentsCASP3 protein, humanCASP8 protein, humanCaspase 3Caspase 8FAS protein, humanfas ReceptorPolysaccharidesTNF-Related Apoptosis-Inducing LigandTNFSF10 protein, human

Identifiers

PMID28727820
PMCPMC5519206
OpenAlexW2738527595

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.